Mr. Termeer was a leader of the biotechnology industry and a mentor to many entrepreneurs, executives and researchers, including the X4 team. He had a long and illustrious career with numerous contributions to the biotech community until his death in May 2017. He was the Chairman, President and Chief Executive Officer of Genzyme Corporation, a Fortune 500 company, a position he held for over 25 years before he retired in 2011 following the acquisition of Genzyme by Sanofi in a transaction valued at more than $20 billion. Mr. Termeer served as a board member of Massachusetts Institute of Technology Corporation and on its executive committee, a director of Massachusetts General Hospital, board member of Partners HealthCare, a member of the Board of Fellows of Harvard Medical School, and on the board of the Biotechnology Industry Organization (BIO). He also served on the boards of Abiomed, Inc., AVEO Pharmaceuticals, Verastem, Inc., and Medical Simulation Corporation. He was a Founder of X4 and several other Boston-area biotechnology companies. In 2008, he was appointed to Massachusetts Governor Deval Patrick’s Council of Economic Advisors and he was a co-chair of the Leadership Council of the Massachusetts Life Sciences Collaborative. He was elected a fellow of the American Academy of Arts and Sciences in 1999. Mr. Termeer studied economics at Erasmus University in the Netherlands and earned an MBA from the Darden School at the University of Virginia.
Keith Flaherty, MD
Dr. Flaherty is Director of the Henri and Belinda Termeer Center for Targeted Therapies at the Cancer Center at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School. Dr. Flaherty's research focuses on the understanding of novel, molecularly targeted therapies in cancer and to define the mechanisms of action and resistance of novel therapies. Dr. Flaherty received his medical degree from Johns Hopkins University. Dr. Flaherty trained in internal medicine at Brigham and Women’s Hospital and completed a medical oncology fellowship at the University of Pennsylvania.
Renato Skerlj, PhD
Dr. Skerlj is Chief Scientific Officer at X4. He has twenty-five years of experience leading the discovery and development of small molecule drugs to treat rare diseases, cancer, infection and neurodegenerative diseases and deep scientific expertise in the research and development of innovative, genetically-targeted treatments. Most recently, Dr. Skerlj held drug discovery and development leadership roles at Cambridge-based company Lysosomal Therapeutics, Inc. Prior to that, he was interim Head of Small Molecule Discovery at Genzyme, and was part of the executive team at AnorMED, a publicly-traded company that was acquired by Genzyme in 2006. Dr. Skerlj is the co-inventor of both plerixafor, a stem cell mobilizer approved by the U.S. Food and Drug Administration (FDA) in 2008, and ertapenem, an anti-bacterial approved by the FDA in 2001, and has been responsible for delivering multiple drug candidates into early clinical research. He has authored 65 publications and holds 50 patents. Dr. Skerlj received his Ph.D. in Synthetic Organic Chemistry from the University of British Columbia and completed postdoctoral fellowships at the University of Oxford and Ohio State University.
Richard Peters, MD, PhD
Dr. Peters is currently Chief Executive Officer of Yumanity Therapeutics. Most recently, Dr. Peters was the President and Chief Executive Officer of Merrimack Pharmaceuticals. Prior to that, he was Senior Vice President and Head of Rare Diseases at Sanofi Genzyme and the Division Medical Officer of Sanofi’s Hematology and Oncology Division. Dr. Peters has over 20 years of biotech experience including roles of increasing responsibility in medical affairs at Amgen, Onyx and Genzyme. Earlier in his career, Dr. Peters was Chief Executive Officer of Mednav. Dr. Peters graduated with his MD and Ph.D. from Medical University of South Carolina.
Paula Ragan, PhD
Dr. Ragan has been X4’s President and Chief Executive Officer and a member of the X4 Board of Directors since July 2014. She has more than 18 years of experience building companies in the biotechnology industry. From August 2012 to September 2014, Dr. Ragan consulted as Chief Business Officer at Lysosomal Therapeutics Inc., a private biopharmaceutical company, where she led the company’s business development activities. Prior to that, from January 2007 to August 2012, Dr. Ragan held leadership roles in corporate development and operations at Genzyme Corporation, a Sanofi company, where she led strategic partnering efforts for Genzyme’s Rare Disease business and headed the supply chain planning for Genzyme’s flagship commercial products. Other professional roles include business roles at Hydra Biosciences, Oscient Corporation and Celera Corporation. Dr. Ragan received her B.S. from Tufts University and her Ph.D. from Massachusetts Institute of Technology and completed post-doctoral studies at Harvard Medical School.